This study aims to determine the oncological effectiveness of adjuvant HIPEC, using
intraperitoneal oxaliplatin with concomitant i.v. 5-FU/LV, following a curative resection of
a T4 or intra-abdominally perforated Colon cancer in preventing the development of peritoneal
carcinomatosis in addition to the standard adjuvant systemic treatment.
Hypothesis:
The hypothesis is that adjuvant HIPEC preceding routine adjuvant systemic therapy using i.p.
oxaliplatin with concomitant i.v. 5-FU/LV following a curative resection of a T4 or
intra-abdominally perforated colon cancer reduces the development of peritoneal
carcinomatosis in comparison to standard adjuvant systemic treatment alone.
Phase:
Phase 3
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators:
Dutch Health Care Insurance Board ZonMw: The Netherlands Organisation for Health Research and Development